Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Clarient launches new prostate cancer test
This new test will be available through Clarient’s PATHSiTE virtual reporting tool and accessible to the company’s entire pathology network. Clarient said that the new test is based
This new test will be available through Clarient’s PATHSiTE virtual reporting tool and accessible to the company’s entire pathology network. Clarient said that the new test is based
Interferon-omega is part of the interferon family of proteins which are naturally produced by the immune system. This patented gene-based composition was discovered and developed by Vical scientists
Mr Sanger served as the chairman of General Mills from 1995 until his retirement in 2008. He joined General Mills in 1974 and held a variety of positions
In October 2007, Galapagos announced an alliance agreement with Janssen providing Janssen with option rights to acquire worldwide, commercial licenses to novel small-molecules from up to 12 of
The collaboration combines Beactica’s unique approach to fragment-based drug discovery and GE Healthcare’s Biacore technology with enzymology expertise from Uppsala University, said Beactica. Under the terms of the
This approval strengthens the company’s position in the growing Asian market through direct entities and confirms its position as a global spine solution company, said LDR. LDR added
MaxGuard is claimed to be the first positive displacement needleless connector featuring impregnation of the antimicrobial additive into each of the components of the device. Laboratory testing has
The agency has completed its review of the response that Merck provided in July 2008 and has recommended that Merck submit additional data when the 48 month study
In this trial, which included an intensive diet and exercise behavior modification regimen, obese patients treated with Contrave, based on intent-to-treat and completer analyses, lost an average of
The Phase I proof of concept study compared intravenous CNS 7056 to placebo and a standard dose of midazolam, the current gold standard for procedural sedation. The anticipated